GIỚI THIỆU VỀ TẬP NÀY
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.
Tiếng Anh
Hoa Kỳ
BẢN CHÉP ÂM THANH 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
TÌM KIẾM CÁC TẬP TRƯỚC
Tìm kiếm các tập trước của Pharmaceutical Executive.
CÁC TẬP KHÁC TRONG PODCAST NÀY
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
Bausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services, and a LogiPharma 2026 conversation makes the case against waiting for perfect data to deploy AI in pharma supply chains.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Tuyên bố miễn trừ trách nhiệm: Podcast và tác phẩm nghệ thuật được nhúng trên trang này là của Pharmaceutical Executive Podcast, là tài sản của chủ sở hữu và không được liên kết hoặc xác nhận bởi Listen Notes, Inc.
CHỈNH SỬA
Cảm ơn bạn đã giúp cơ sở dữ liệu podcast luôn cập nhật.
